AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: ATYR
Report Date: 2026-05-06
Full Report: https://amaly.io/stock/ATYR

EXECUTIVE SUMMARY
------------------
Compliance Status: COMPLIANT
Quality Rating: AAA
Description: aTyr Pharma, Inc. (ATYR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for pulmonary diseases. This report evaluates its Shariah compliance across financial, business activity, and ESG dimensions using global and regional standards. The company demonstrates strong compliance with financial screening criteria, with low debt and negligible non-compliant income. Inclusion in major Shariah indices confirms its suitability for Islamic investment portfolios. Overall, ATYR presents a low-risk, compliant investment opportunity in the healthcare sector.

Primary Compliance Concerns:
- Minor ongoing securities litigation requiring monitoring, but no material Shariah impact

Purification Requirement: 3.05%
Index Inclusion: Included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, and Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 0.0%
Liquidity Ratio: 0.0%
Interest Income Ratio: 0.0%
Purification Required: 3.05%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: INCLUDED
MSCI Islamic: INCLUDED
DJIM: INCLUDED
FTSE Shariah: INCLUDED
Total: 4 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2024
Latest Quarterly Data: Q3 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-01-30T12:00:00Z

---
Full interactive report: https://amaly.io/stock/ATYR
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.